Clinical Outcomes of Patients With COVID19 | NCT04280913

Studies
Clinical Outcomes of Patients With COVID19

NCT04280913

Sponsor

Guangzhou Institute of Respiratory Disease

Status

Withdrawn

Last Update Posted

Mar 19, 2020Actual

Enrollment

0Actual

Phase

Not provided

Conditions

Coronavirus Disease 2019

Interventions

retrospective analysis

Countries

China

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Mar 2020

Overall Recruitment Status or Expanded Access Status

Withdrawn

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

The research project was changed.

Expanded Access Info

Start Date

Feb 22, 2020Actual

Primary Completion Date

Mar 31, 2020Estimated

Completion Date

Mar 31, 2020Estimated

First Submitted Date

Feb 20, 2020

First Submission Date that Met QC Criteria

Feb 20, 2020

First Posted Date

Feb 21, 2020Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Mar 17, 2020

Last Update Posted Date

Mar 19, 2020Actual

Sponsor/Collaborators Module

Responsible Party, by Official Title

LuQian Zhou, Principal Investigator, Guangzhou Institute of Respiratory DiseasePrincipal Investigator

Lead Sponsor

Guangzhou Institute of Respiratory DiseaseOTHER

Collaborators

Name	Class
Huizhou Municipal Central Hospital	OTHER

Oversight Module

Has Data Monitoring Committee (DMC)

Not provided

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. The number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

0Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
COVID-19 patients		Hospitalized patients with COVID-19	Other: retrospective analysis

Interventions

Name	Type	Description	Arm Group Labels	Other Names
retrospective analysis	Other	The investigators retrospectively analyzed the hospitalized patients with COVID-19.	COVID-19 patients

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Time to negative conversion of severe acute respiratory syndrome coronavirus 2	The primary outcome is the time to negative conversion of coronavirus	1 month

Secondary Outcomes

Measure	Description	Time Frame
Length of stay in hospital	The time of hospitalization.	1 month
Survival	The rate of survival within hospitalization of these patients will be tracked.

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Hospitalized patients with COVID19

Exclusion Criteria:

Suspected patients with COVID19, not confirmed by the laboratory
Patients who are refused to receive medical treatments

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

This is a retrospective study of hospitalized patients with COVID19.

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Luqian Zhou, MD	The First Affiliated Hospital of Guangzhou Medical University	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
HuiZhou Municipal Central Hospital		Huizhou	Guangdong	516001	China

Condition Browse Module

MeSH Terms

ID	Term
D000086382	COVID-19

Ancestor Terms

ID	Term
D011024	Pneumonia, Viral
D011014	Pneumonia
D012141	Respiratory Tract Infections
D007239	Infections

Browse Leaves

Not provided

Browse Branches

Not provided